TriaGen Wealth Management’s Boston Scientific BSX Stock Holding History

TriaGen Wealth Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,619	Closed	-$2.25M	–	175
2025 Q4	$2.25M	Sell	23,619 -106	-0.4%	-$10.4K	0.58%	47
2025 Q3	$2.32M	Sell	23,725 -46	-0.2%	-$4.76K	0.6%	48
2025 Q2	$2.55M	Sell	23,771 -1,160	-5%	-$117K	0.77%	29
2025 Q1	$2.52M	Sell	24,931 -441	-2%	-$44.4K	0.89%	24
2024 Q4	$2.27M	Sell	25,372 -22	-0.1%	-$1.94K	0.76%	31
2024 Q3	$2.13M	Hold	25,394	–	–	0.71%	34
2024 Q2	$1.96M	Sell	25,394 -148	-0.6%	-$10.8K	0.76%	41
2024 Q1	$1.75M	Sell	25,542 -7	-0%	-$450	0.73%	44
2023 Q4	$1.48M	Sell	25,549 -229	-0.9%	-$12.2K	0.7%	46
2023 Q3	$1.36M	Sell	25,778 -163	-0.6%	-$8.55K	0.69%	47
2023 Q2	$1.4M	Hold	25,941	–	–	0.64%	55
2023 Q1	$1.3M	Sell	25,941 -281	-1%	-$13.2K	0.65%	50
2022 Q4	$1.21M	Buy	+26,222	New	+$1.14M	0.67%	43
2021 Q4	–	Sell	-11,796	Closed	-$512K	–	184
2021 Q3	$512K	Buy	+11,796	New	+$522K	0.28%	98

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TriaGen Wealth Management's BSX Position: Q1 2026 in Review

TriaGen Wealth Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 23,619 shares — an estimated $2.25M sold.

TriaGen Wealth Management first reported a position in BSX in Q3 2021 and held it in 14 quarters. The position peaked at $2.55M in Q2 2025. 1,679 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

TriaGen Wealth Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
TriaGen Wealth Management sold 23,619 Boston Scientific shares in Q1 2026, an estimated $2.25M.
TriaGen Wealth Management first reported a position in Boston Scientific in Q3 2021 and held it in 14 quarters.
TriaGen Wealth Management's Boston Scientific position peaked at $2.55M in Q2 2025.
1,679 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on TriaGen Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.